October 7 (SeeNews) - Bulgarian drug maker Sopharma [BUL:3JR] said on Monday that its sales revenue edged up by an annual 2% in the January-September period of 2019, due to higher sales on foreign markets.
Sopharma's domestic sales fell 9% year-on-year in the first nine months of 2019, while sales abroad rose 10%, the company said in a bourse filing.
In September alone, the company's sales jumped 31%. Exports were 66% higher on the year, while domestic sales lost 5%.
The company did not disclose information about the volume of its sales or amount of sales revenue.
As at 12:45 CET on Monday, Sopharma shares traded at 3.34 levs ($1.88/1.71 euro), unchanged from their previous closing price on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)